source
- Paragon spinout Velaris Therapeutics goes public via reverse merger with Alaunos, raising $350 millionParagon Labs, a biotechnology incubator, announced that its latest spinout, Velaris Therapeutics, became a public company through a reverse merger with Alaunos Therapeutics. The transaction places…
- Novartis secures supplemental FDA approval to market repurposed antibiotic Lamprene in the USNovartis has obtained a supplemental approval from the U.S. Food and Drug Administration for its drug Lamprene, allowing it to be sold as an antibiotic. Lamprene, originally developed decades ago…